中科微点-全球专利检索

  1. Login
  2. Sign Up

Search Results

6 records (took 0.017 seconds)

    Targeting abnormal DNA repair in therapy-resistant breast and pancreatic cancers
    2.
    发明授权
    Targeting abnormal DNA repair in therapy-resistant breast and pancreatic cancers 有权
    针对耐药性乳腺癌和胰腺癌的异常DNA修复

    公开(公告)号：US09132120B1

    公开(公告)日：2015-09-15

    申请号：US13783785

    申请日：2013-03-04

    Applicant: STC.UNM ,  University of Maryland, Baltimore

    Inventor： Alan Edward Tomkinson ,  Feyruz Rassool

    IPC: A61K31/4184 ,  C40B40/06 ,  A61K31/165

    CPC classification number: A61K31/4184 ,  A61K31/00 ,  A61K31/165 ,  A61K45/06 ,  C12Q1/00 ,  C12Q1/6886 ,  C12Q2600/106 ,  C12Q2600/158 ,  G01N33/57407 ,  G01N33/57434 ,  G06F19/00 ,  G06F19/20 ,  G06F19/3456 ,  Y02A90/26 ,  A61K2300/00

    Abstract: In one embodiment, the invention provides a method of treating a subject suffering from a breast cancer tumor which is non-responsive or intrinsically resistant to anti-estrogen therapy comprising administering a therapeutically effective amount of an inhibitor of alternative (ALT) non-homologous end joining (NHEJ) factor to the subject.In another embodiment the invention provides a method of treating a subject who suffers from a pancreatic cancer which is non-responsive to chemotherapy and/or radiation comprising co-administering a therapeutically effective amount of PARP1 inhibitor and a DNA ligase IIIα inhibitor to the subject. Related diagnostic methods, nucleic acid arrays, devices and kits are also provided.

    Abstract translation: 在一个实施方案中，本发明提供了治疗患有对抗雌激素疗法无反应或本质上抗性的乳腺癌肿瘤的受试者的方法，其包括施用治疗有效量的替代（ALT）非同源末端的抑制剂 加入（NHEJ）因素。 在另一个实施方案中，本发明提供了治疗患有对化学疗法和/或放射线无反应的胰腺癌的受试者的方法，包括向受试者共同施用治疗有效量的PARP1抑制剂和DNA连接酶IIIα抑制剂。 还提供了相关的诊断方法，核酸阵列，装置和试剂盒。

    TARGETING ABNORMAL DNA REPAIR IN THERAPY-RESISTANT BREAST AND PANCREATIC CANCERS
    3.
    发明申请
    TARGETING ABNORMAL DNA REPAIR IN THERAPY-RESISTANT BREAST AND PANCREATIC CANCERS 审中-公开
    针对耐药性乳腺癌和胰腺癌的异常DNA修复

    公开(公告)号：US20160051517A1

    公开(公告)日：2016-02-25

    申请号：US14793878

    申请日：2015-07-08

    Applicant: STC.UNM ,  UNIVERSITY OF MARYLAND, BALTIMORE

    Inventor： Alan Edward Tomkinson ,  Feyruz Rassool

    IPC: A61K31/4184 ,  C12Q1/68 ,  G06F19/20 ,  A61K31/165

    CPC classification number: A61K31/4184 ,  A61K31/00 ,  A61K31/165 ,  A61K45/06 ,  C12Q1/00 ,  C12Q1/6886 ,  C12Q2600/106 ,  C12Q2600/158 ,  G01N33/57407 ,  G01N33/57434 ,  G06F19/00 ,  G06F19/20 ,  G06F19/3456 ,  Y02A90/26 ,  A61K2300/00

    Abstract: In one embodiment, the invention provides a method of treating a subject suffering from a breast cancer tumor which is non-responsive or intrinsically resistant to anti-estrogen therapy comprising administering a therapeutically effective amount of an inhibitor of alternative (ALT) non-homologous end joining (NHEJ) factor to the subject.In another embodiment the invention provides a method of treating a subject who suffers from a pancreatic cancer which is non-responsive to chemotherapy and/or radiation comprising co-administering a therapeutically effective amount of PARP1 inhibitor and a DNA ligase IIIα inhibitor to the subject. Related diagnostic methods, nucleic acid arrays, devices and kits are also provided.

    Abstract translation: 在一个实施方案中，本发明提供了治疗患有对抗雌激素疗法无反应或本质上抗性的乳腺癌肿瘤的受试者的方法，其包括施用治疗有效量的替代（ALT）非同源末端的抑制剂 加入（NHEJ）因素。 在另一个实施方案中，本发明提供了治疗患有对化学疗法和/或放射线无反应的胰腺癌的受试者的方法，包括向受试者共同施用治疗有效量的PARP1抑制剂和DNA连接酶IIIα抑制剂。 还提供了相关的诊断方法，核酸阵列，装置和试剂盒。

Patent Agency Ranking